Last update:

Clinical pharmacology news

A popular joint pain supplement may accelerate dementia

New research has found an association between taking glucosamine, a popular over-the-counter supplement used for joint pain, and a higher likelihood of progressing from mild cognitive impairment to Alzheimer's disease. The ...

New Lassa fever vaccine shows promising results for first-in-human clinical trial

Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health, or CVD, report encouraging results from an early clinical trial that tested a new dual vaccine against Lassa ...

New drug could slow the development of Alzheimer's

"Compound 10" is how Ursula Quitterer refers to the chemical compound that her team has developed and that could slow the progression of Alzheimer's disease. Quitterer is a professor of molecular pharmacology at ETH Zurich ...

Africa races for Ebola vaccine as outbreak outpaces response

Researchers racing to develop a vaccine to fight the growing Ebola outbreak centered in the Democratic Republic of the Congo (DRC) say doses could be ready for human testing within "two to three months," while the more promising ...

Hay fever, antihistamines and the evidence on dementia risk

For millions of people around the world, pollen season means weeks of sneezing, itchy eyes, and a blocked or runny nose. The timing varies depending on where you live and which plants are in flower, but grass pollen is one ...

Flu drugs show promise against cognitive decline

A class of flu drugs may reduce cognitive decline and premature aging in people living with chronic viral infection, reports a new study led by Northwestern University that began with blood samples from people with HIV and ...